Novocure rises after FDA accepts premarket application for cancer treatment

NovoCure

18/01/2024 13:51

** Shares of Novocure  NVCR.O  rise 3.5% to $12.86 premarket
    ** Company says the U.S. FDA has accepted its application
for premarket approval for its device Tumor Treating Fields, for
a type lung cancer, in combination with either chemotherapy or a
cancer immunotherapy
    ** NVCR expects to receive a regulatory decision from the
FDA in H2 2024
    ** Up to Wednesday's close, stock down 86.5% in the last 12
months 

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))